Solventum Corporation
$83.27
+1.42 · +1.73% today
Market open · updated 12:44:26 PM ET
- High
- $83.19 10:20 AM
- Low
- $81.53 3:00 PM
Against the S&P 500 Price change through Oct 27, 2026
SOLV+4.72%
S&P 500+12.87%
SOLV+15.28%
S&P 500+12.32%
SOLV—
S&P 500+87.41%
SOLV—
S&P 500+69.55%
Key numbers
- Previous close
- $81.85
- Open
- $82.27
- Day's range
- $82.25 – $83.68
- 52-week range
- $62.38 – $94.16
- Volume
- 435,736
- Average volume
- 1.1 million
- Market value
- $14.2 billion
- Price to earnings
- 10.4last 12 months
- Earnings per share
- $8.27last 12 months
- Beta
- 0.70moves less than the market
- Dividend
- None
- 50-day average
- $88.33
- 200-day average
- $78.34
Thursday, Nov 5, 2026, after the close.
Analyst price targets and the full financials are in the terminal.
Who Solventum buys from and competes with From our value chain
Solventum in the news
- HeadlineSOLV Wins FDA Clearance to Combine Restrata Matrix With V.A.C.TherapyZacks Investment Research · October 23, 2026 at 1:20 PM ET
- HeadlineSOLV Energy to Report Third Quarter 2026 Financial Results on November 12, 2026GlobeNewsWire · October 22, 2026 at 7:05 AM ET
- Company earningsThermo Fisher Scientific tops Q3 estimates, but shares slide premarketWiseView Research desk · October 21, 2026
- HeadlineSolventum Announces FDA 510(k) Clearance for Combined Use of Restrata™ Matrix and Solventum™ V.A.C.® Therapy*PRNewsWire · October 19, 2026 at 4:05 PM ET
- HeadlineSolventum to Report Third Quarter Fiscal 2026 Earnings on November 5, 2026PRNewsWire · October 15, 2026 at 4:05 PM ET
- CongressAlan Armstrong bought $1,001 - $15,000 of SOLVSenate filing · disclosed Jul 22, 2026
- CongressRo Khanna bought $1,001 - $15,000 of SOLVHouse filing · disclosed Jun 11, 2026
- CongressJames French Hill sold $15,001 - $50,000 of SOLVHouse filing · disclosed Jan 26, 2026
Earnings
Next report: Thursday, Nov 5, 2026, after the close.
Congress trades in SOLV
2 purchases and 3 sales in the latest 5 filings.
| Member | Trade | Amount | Traded | Disclosed |
|---|---|---|---|---|
| Alan ArmstrongSenate · R-Oklahoma | Purchase | $1,001 - $15,000 | Mar 27, 2026 | Jul 22, 2026 |
| Ro KhannaHouse · D-California | Purchase | $1,001 - $15,000 | May 1, 2026 | Jun 11, 2026 |
| James French HillHouse | Sale | $15,001 - $50,000 | Dec 31, 2025 | Jan 26, 2026 |
| Ron WydenSenate | Sale | $1,001 - $15,000 | Feb 6, 2025 | Feb 21, 2025 |
| Julie JohnsonHouse · D-Texas | Sale | $1,001 - $15,000 | Jan 15, 2025 | Feb 13, 2025 |
Source: Periodic transaction reports filed with the House and the Senate · Members disclose ranges, not exact amounts, and may file weeks after the trade.
About Solventum
Solventum Corporation, established in 2023 and headquartered in Saint Paul, Minnesota, operates as a healthcare entity dedicated to pioneering, producing, and commercializing diverse solutions that address critical needs for both customers and patients. The company's business activities are organized into four principal segments.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Employees
- 20,584
- Headquarters
- Eagan, Minnesota
- Website
- solventum.com
- Listed
- Apr 1, 2024
More medical - instruments & supplies stocks
The price refreshes every 15 seconds while the market is open and carries the time it was read. Company figures are updated each evening. Built from WiseView and market data and public filings. For information only, not investment advice.